Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma that is refractory to current therapeutic options.
n engl j med 381;8 nejm.org August 22, 2019 D espite the availability of proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies for multiple myeloma, most patients will have a relapse and refractory disease will develop. An increasing number of patients have tripleclass refractory myeloma, defined as disease refrac tory to proteasome inhibitors, immunomodula tory agents, and monoclonal antibodies, with most patients being treated with all five agents currently in use (carfilzomib, bortezomib, lena lidomide, pomalidomide, and daratumumab; i.e., pentaexposed). Overall survival in patients with myeloma refractory to these classes is short; patients with daratumumabrefractory myelo ma have a median overall survival of 1.7 to 3.0 months. 14 Currently, these patients have no treatment options with proven clinical benefit. 4, 5 Exportin 1 (XPO1) -the sole known nuclear exporter of tumor suppressor proteins, the gluco corticoid receptor, and oncoprotein messenger RNAs (mRNAs) -is overexpressed in myeloma and correlates with increased bone disease and shorter survival. 611 Selinexor, which was recently approved by the Food and Drug Administration, is a potent, oral, selective inhibitor of nuclear export that binds to Cys528 in the cargobinding pocket of XPO1, 1214 forcing the nuclear localiza tion and functional activation of tumorsuppres sor proteins, trapping IκBα in the nucleus to suppress nuclear factor κB activity, and prevent ing oncoprotein mRNA translation. 9, 10, 15 Selective induction of apoptosis in malignant hemato logic and solid tumor cells is a result. 9 Preclini cal studies have shown that selinexor with or without dexamethasone induces apoptosis in a number of myeloma cell lines and has antitumor activity in animal models. 3, 8, 9, 16, 17 Administration of selinexor (80 mg) with dexamethasone (20 mg) according to two dosing schedules had been evaluated among patients with myeloma refractory to either four or five drugs in Part 1 of the phase 2 STORM (Selinex or Treatment of Refractory Myeloma) study. 18 In that heterogeneous population, 21% of patients had a partial response or better. On the basis of those findings, the activity of selinexor at a dose of 80 mg twice weekly was examined in a more uniform population in the pivotal STORM Part 2 study.
Me thods

Trial Design and Oversight
The STORM study was a phase 2b, multicenter, openlabel study involving patients enrolled from May 2015 through March 2018 at 60 sites in the United States and Europe. The institu tional review board or independent ethics com mittee at each study center approved the proto col (available with the full text of this article at NEJM.org), and the study was performed in ac cordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The study was designed by the sponsor (Karyo pharm Therapeutics). Disease response was ad judicated by an independent review committee of four physicians. The sponsor collected the data and analyzed them in conjunction with the authors. A professional medical writer, funded by the sponsor, wrote the first draft of the manuscript under close direction of the authors. The authors reviewed and revised the manu script, had access to all data, and vouch for the completeness and accuracy of the data and for the adherence of the study to the protocol.
Patients
Eligible patients had measurable myeloma accord ing to International Myeloma Working Group (IMWG) criteria 19, 20 (see the Supplementary Ap pendix, available at NEJM.org); had previously received treatment with bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, glu cocorticoids, and an alkylating agent; and had disease refractory to at least one immunomodu latory drug, one proteasome inhibitor, daratumu mab, glucocorticoids, and their most recent regimen. Refractory disease was defined as progression during treatment or within 60 days after completion of therapy, or less than 25% response to therapy. 19, 20 An Eastern Cooperative Oncology Group performancestatus score of 0 to 2 (scores range from 0 to 5, with higher scores reflecting greater disability) and adequate hepatic function, renal function, and hemato poietic function were required. Systemic light chain amyloidosis, active central nervous system involvement, peripheral neuropathy of grade 3 or higher, or painful neuropathy of grade 2 or higher were exclusion criteria. A full list of inclu sion and exclusion criteria is provided in Table S1 in the Supplementary Appendix. Written informed consent was obtained from all patients before enrollment.
Treatment
Oral selinexor (80 mg) in combination with dexamethasone (20 mg) was administered on days 1 and 3, weekly, in 4week cycles until dis ease progression, death, or discontinuation. A dosemodification protocol was used for the management of adverse events (Tables S2 and S3 in the Supplementary Appendix). All patients were required to receive 8 mg of ondansetron (or equivalent) before the first dose of study drug and two or three times daily as needed. Other antiemetics (olanzapine and neurokinin1 recep tor antagonists) were permitted for patients with unacceptable side effects to ondansetron (or its equivalent) or with persistent nausea. Supportive measures were provided at the discretion of the investigator and may have included intravenous fluids, hematopoietic growth factors, transfu sions, appetite stimulants (olanzapine and meges trol acetate), or a combination of these.
End Points and Assessments
The primary end point was overall response, defined as a confirmed partial response (≥50% reduction in the serum level of myeloma protein) or better, with response adjudicated by the inde pendent review committee. 21 Secondary end points included response duration; clinical benefit, de fined as a confirmed minimal response (≥25 to <50% reduction in the serum level of myeloma protein) or better; progressionfree survival; and overall survival. (Definitions of end points are provided in the Supplementary Appendix.) Disease specific assessments were conducted at baseline, day 1 of each treatment cycle, and at the time of disease progression or suspected response. High risk cytogenetic abnormalities included del(17p), t(4;14), t(14;16), and gain(1q) chromosomal abnor malities on fluorescence in situ hybridization. 22 Quality of life was assessed with the Functional Assessment of Cancer Therapy-Multiple Myeloma questionnaire (see the protocol). Safety and side effect profile were assessed through history tak ing, physical examination, laboratory assessments, and 12lead electrocardiography. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Ad verse Events, version 4.03. 23
Pharmacodynamics and Response Predictor
Methods regarding measurement of XPO1 mRNA induction and immunohistochemical analysis of glucocorticoid receptor induction are included in the Supplementary Appendix. A predictive bio marker of response to selinexor was sought in patients with myeloma with the use of the VIPER (Virtual Inference of Proteinactivity by Enriched Regulon analysis) algorithm, which can trans form geneexpression profiles from tumor sam ples into accurate predictions of protein activ ity for approximately 6000 regulatory proteins (DarwinHealth) (see the Supplementary Appen dix). 24 RNA levels in CD138+ cells that were isolated from the pretreatment bone marrow aspirate of patients enrolled in the STORM Part 2 study were used for this analysis.
Statistical Analysis
The sample size was based on assumptions for pentaexposed, tripleclass refractory myeloma with a minimal threshold of 10% of patients with a partial response or better. 19 For the pri mary efficacy analysis, a sample of 122 patients allowed for a onesided test at an alpha level of 0.025 to detect a minimum of 20% of patients with a partial response or better against a value of 10% under the null hypothesis with 90% power. The modified intentiontotreat popula tion was used for the primary efficacy analysis; this population comprised all enrolled patients who met all eligibility criteria or received a waiver to enroll from the sponsor (12 patients; waivers were granted only in situations in which patient safety was not compromised and the scientific integrity of the study was not affected) and who received at least one dose of selinexor plus dexamethasone. The safety population in cluded all patients who received at least one dose of study drug. The primary analysis used a two sided, exact 95% confidence interval, calculated for the percentage of patients with a partial response or better in the modified intentionto treat population, with statistical significance declared if the lower boundary of this interval
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was more than 10%. Summary statistics were computed and displayed for each of the defined analysis populations and according to each as sessment time point. Summary statistics for con tinuous variables minimally included number, mean, standard deviation, minimum, median, and maximum. For categorical variables, frequen cies and percentages are presented. For timeto event variables, the Kaplan-Meier method was used for descriptive summaries.
R esult s Patients
A total of 123 patients were enrolled, all of whom were included in the safety population ( Fig. S1 in the Supplementary Appendix). One patient did not meet full eligibility criteria (no previous carfilzomib); therefore, 122 patients were included in the modified intentiontotreat population. The median age was 65.2 years, and the median duration of myeloma was 6.6 years; 53% of the patients had highrisk cytogenetic abnormalities ( Table 1 , and Table S4 in the Supplementary Appendix). All patients had pro gressive myeloma at the time of enrollment, and the disease was typically rapidly progressive: 107 patients (88%) with available data on myeloma protein levels at both screening and the first day of therapy (median, 12 days) had a median in crease in disease burden of 22%. Creatinine clearance was less than 60 ml per minute in 39 patients (32%) and less than 40 ml per minute in 14 patients (11%). The median number of previous therapies was 7 (range, 3 to 18); 86 patients (70%) had previously received daratumu mab in combination with other agents, 102 (84%) had previously undergone stemcell transplanta tion, and 2 (2%) had previously received chime ric antigen receptor Tcell (CART) therapy. In the modified intentiontotreat population, all pa tients had pentaexposed myeloma that was re fractory to at least one proteasome inhibitor, one immunomodulatory drug, and daratumumab, as required by the protocol. A total of 83 patients (68%) were documented to have pentarefractory myeloma. It is notable that 96% of the patients had myeloma that was refractory to the most potent agent of each class: carfilzomib, pomalid omide, and daratumumab (Table 1) .
Treatment Duration and Doses
Of the 123 patients enrolled, 118 (96%) discon tinued treatment, with disease progression and adverse events the most common reasons ( (Fig. 1 ). The median progressionfree survival was 3.7 months (95% CI, 3.0 to 5.3), and the median overall survival was 8.6 months (95% CI, 6.2 to 11.3) ( Fig. 2A and 2B ). In patients who had a partial response or better or a minimal response or bet ter, the median overall survival was 15.6 months ( Fig. 2C ).
Safety Profile
The most common adverse events that emerged during treatment were thrombocytopenia (in 73% of the patients), fatigue (in 73%), nausea (in 72%), and anemia (in 67%) ( Table 3 ). The most common grade 3 or 4 adverse events were thrombocytopenia (in 59% of the patients), ane mia (in 44%), hyponatremia (in 22%), and neu tropenia (in 21%). Thrombocytopenia occurred more frequently in patients who had thrombocy topenia at baseline than in those who did not ( Fig. S2 * A total of 123 patients were enrolled; 1 patient did not meet eligibility criteria, so 122 patients were included in the modified intention-to-treat population. Percentages may not total 100 because of rounding. † Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores reflecting greater disability. ‡ This category includes any of del(17p)/p53, t(14;16), t(4;14), or 1q21 (1q gain >2). § The disease was defined as refractory to an antimyeloma therapy if the best response to the therapy was stable disease or worse or if the patient had progression or a relapse either during treatment or within 60 days after discontinuing the therapy. ¶ Myeloma that was refractory to these five agents was considered to be penta-refractory. dexamethasone, although such determinations for a new agent are imprecise ( Table S5 in the Supplementary Appendix). Adverse events lead ing to dose modification or interruption oc curred in 80% of the patients, with the majority of events occurring in the first two cycles. The most common adverse events leading to dose reduction or interruption were thrombocytope nia (in 43% of the patients), fatigue (in 16%), and neutropenia (in 11%). Supportive care -in cluding granulocyte colonystimulating factors, thrombopoietinreceptor agonists, appropriate fluid and caloric intake, appetite stimulants, psychostimulants, and additional antinausea agents -usually reduced the intensity or dura tion of adverse events. Side effects were revers ible without evidence of toxic effects in major organs (treatmentrelated cardiac, pulmonary, hepatic, or renal dysfunction of grade 3 or higher) or cumulative toxic effects, with irreversible acute kidney injury reported in one patient (1%).
Serious adverse events occurred in 63% of the patients, with pneumonia (in 11%) and sepsis (in 9%) being the most common ( Table S6 in the Supplementary Appendix). A total of 28 patients died during the study -16 from disease pro gression and 12 from an adverse event. In the 12 patients with these adverse events, 2 events were assessed by the investigator as being related to treatment (pneumonia with concurrent disease progression [in 1 patient] and sepsis [in 1]).
Biomarkers of Selinexor Response in Multiple Myeloma
The binding of selinexor to XPO1 leads to rapid inactivation of nuclear export, XPO1 protein deg radation, and induction of XPO1 mRNA tran scription (without new protein production). 9 XPO1 mRNA induction is one pharmacodynamic mark er in selinexortreated patients, as observed from blood samples obtained before and after selinexor administration, as well as enhanced glucocorti * Overall response was defined as a partial response (≥50% reduction in the serum level of myeloma protein) or better, and clinical benefit was defined as a minimal response (≥25% to <50% reduction in the serum level of myeloma protein) or better. Among the 122 patients, the best response to therapy was a stringent complete response in 2 (2%), a very good partial response in 6 (5%), a partial response in 24 (20%), a minimal response in 16 (13%), stable disease in 48 (39%), and progressive disease or disease that could not be evaluated for response in 32 (26%). R-ISS denotes Revised International Staging System. † This category included any of del(17p)/p53, t(14;16), t(4;14), or 1q21 (1q gain >2). coid receptor nuclear localization (Fig. S5 in the Supplementary Appendix). 25, 26 A model based on a linear discriminant analysis classifier that was trained on 35 pretreatment patient samples, includ ing 16 obtained from patients who had a response and 19 from patients who did not have a re sponse, identified four master regulators: IRF3, ARL2BP, ZBTB17, and ATRX (Fig. S7 in the Sup plementary Appendix). The fourprotein classifier had a high predictive performance according to leaveoneout crossvalidation (area under the receiveroperatingcharacteristic curve [AUC], 0.862; 95% CI, 0.741 to 0.982). The fourprotein classifier was then validated in an independent, blinded analysis of 12 samples obtained from patients with myeloma who were enrolled in Parts 1 and 2 of the STORM study (AUC, 0.770; 95% CI, 0.456 to 1.000). Specifically, four of five patients who had a response and six of seven who did not have a response to selinexor were correctly identified by the marker, yielding a prediction accuracy of 83% (95% CI, 55 to 95). Training the classifier with the use of differential geneexpression data alone produced no effective classification.
Discussion
In this trial, 26% of the patients with penta exposed, tripleclass refractory myeloma who received oral selinexor, a firstinclass XPO1 inhibitor, with dexamethasone twice weekly had a partial response or better. Two patients had stringent complete responses, and 6 had very good partial responses. Although all patients entered the study with progressive disease, 26 (21%) had persistent disease progression or their disease could not be evaluated for response. Among the patients who had a response, efficacy was consistent across subgroups, including pa tients with highrisk cytogenetic abnormalities (53% of the patients).
The results of this study are notable for sev eral reasons. The trial was permissive, allowing patients with reduced renal function, thrombo cytopenia, and neutropenia to enroll. These pa tients were heavily pretreated, with a median of 7 previous therapeutic regimens, including a me dian of 10 unique antimyeloma agents. Patients had rapidly progressing myeloma, with a 22% An asterisk indicates that the patient was still receiving treatment at the date of data cutoff. increase in disease burden in the 12 days from screening to initial therapy. These characteris tics are consistent with the growing population of patients who have exhausted available thera pies but still desire to continue therapy. Given the rapid progression of pentaexposed, tripleclass refractory myeloma, the window of opportunity to prevent further illness and death is small. Therefore, the regimen that was used in the STORM study began with a high dose of selinexor to achieve rapid disease control. Because most patients involved in the study were older and frail, with limited endorgan reserve and at increased risk for adverse events, dose modifica tions were anticipated and were specified along with supportive care in the protocol. The adverse events that were observed in the study were a func tion of dose, schedule, and baseline clinical char acteristics (e.g., cytopenias). Thrombocytopenia, which is due in part to inhibition by selinexor of thrombopoietin signaling in early megakaryo poiesis, was reversible and was managed with dose interruptions and thrombopoietinreceptor agonists. 27 Although this study establishes the activity of selinexor with dexamethasone, com bination regimens are typically used in patients with myeloma. Preclinical studies of selinexor show enhancement of IκB, which supports its synergy in combination with proteasome inhibi tors, additivity with immunomodulatory drugs, and sensitization of myeloma cells to antiCD38 monoclonal antibodies. 2830 In conclusion, the results of the STORM Part 2 study showed that oral selinexor with lowdose dexamethasone induced responses in 26% of pa tients with refractory myeloma. The most com mon toxic effects of grade 3 or higher included thrombocytopenia without bleeding, anemia, neu tropenia without fever, and hyponatremia.
A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.
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